Building A Bridge Of Equivalence To Facilitate And Implement Rapid Process Changes In Gene Therapy Manufacturing


The number of gene therapy candidates in development is growing rapidly, with many advancing toward late-stage trials. The majority of these therapies are based on viral vector delivery. While improvements in manufacturing processes continue, manufacturers remain challenged to quickly implement new technologies for products in late-stage development or that have received approvals. A clear path for establishing equivalency is needed to facilitate more rapid advances in the field and ultimately enable lower-cost gene therapies that reach patients faster than ever.

State of the Gene Therapy Manufacturing Sector

The gene therapy market is currently expanding at approximately 30% annually, based on a review of several recent market research reports. Continued advances in viral vector technologies are enabling safe and efficient delivery of genetic material to a variety of tissues for resolution of genetic deficiencies that lead to many different diseases.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene